

# Jagdeep S S Singh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5917147/publications.pdf>

Version: 2024-02-01

17  
papers

822  
citations

686830

13  
h-index

996533

15  
g-index

17  
all docs

17  
docs citations

17  
times ranked

1294  
citing authors

#	ARTICLE	IF	CITATIONS
1	Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure. <i>Circulation</i> , 2020, 142, 1713-1724.	1.6	144
2	Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial. <i>Diabetes Care</i> , 2020, 43, 1356-1359.	4.3	102
3	A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. <i>European Heart Journal</i> , 2019, 40, 3409-3417.	1.0	100
4	Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. <i>Heart</i> , 2021, 107, 1032-1038.	1.2	90
5	Mean <math>\langle \text{HbA}_{1c} \rangle</math> and mortality in diabetic individuals with heart failure: a population cohort study. <i>European Journal of Heart Failure</i> , 2016, 18, 94-102.	2.9	76
6	Sacubitril/valsartan: beyond natriuretic peptides. <i>Heart</i> , 2017, 103, 1569-1577.	1.2	72
7	Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. <i>Cardiovascular Diabetology</i> , 2016, 15, 97.	2.7	49
8	SGLT2-inhibitors; more than just glycosuria and diuresis. <i>Heart Failure Reviews</i> , 2021, 26, 623-642.	1.7	41
9	Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. <i>BMJ Open</i> , 2017, 7, e018097.	0.8	38
10	Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 3168-3179.	1.4	33
11	Management of Noncardiac Comorbidities in Chronic Heart Failure. <i>Cardiovascular Therapeutics</i> , 2015, 33, 300-315.	1.1	26
12	Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study. <i>ESC Heart Failure</i> , 2021, 8, 4685-4692.	1.4	20
13	Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. <i>Vascular Health and Risk Management</i> , 2015, 11, 283.	1.0	17
14	The "discordant doppelganger dilemma": SGLT2i mimics therapeutic carbohydrate restriction - food choice first over pharma?. <i>Journal of Human Hypertension</i> , 2021, 35, 649-656.	1.0	7
15	Metformin regresses left ventricular hypertrophy in normotensive patients with coronary artery disease without type 2 diabetes mellitus - the met-remodel trial. , 2018, , .		5
16	Effect of metformin on epicardial adipose tissue in patients with coronary artery disease without diabetes: A cardiac MRI substudy of the MET-remodel trial. <i>Obesity Medicine</i> , 2021, 24, 100349.	0.5	1
17	Letter by Singh et al Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)" <i>Circulation</i> , 2021, 144, e38-e39.	1.6	1